Home
Genes
JAK3
News

News Related to JAK3

Related coverage linked through entity extraction aliases.

Aclaris Therapeutics Details TSLP/ITK Pipeline with Multiple Clinical Readouts Expected in Late 2026

Apr 28, 2026

Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.

Alopecia Areata Market Expected to Expand by 2036 with Novel Therapies in Development

Mar 04, 2026

The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.